-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KEVRZlhcz9A7PRJB5KMW/9oDsoUohou7ijixu0oaPjlzEHDrR6dsSg5GpuwyxSV+ 5fkHA5DsIuqUgOL/V+mQJA== 0001016504-04-000027.txt : 20040625 0001016504-04-000027.hdr.sgml : 20040625 20040625093746 ACCESSION NUMBER: 0001016504-04-000027 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040624 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRATED BIOPHARMA INC CENTRAL INDEX KEY: 0001016504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133035216 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31668 FILM NUMBER: 04880896 BUSINESS ADDRESS: STREET 1: 201 ROUTE 22 CITY: HILLSIDE STATE: NJ ZIP: 07205 BUSINESS PHONE: 9739260816 MAIL ADDRESS: STREET 1: 201 ROUTE 22 CITY: HILLSIDE STATE: NJ ZIP: 07205 FORMER COMPANY: FORMER CONFORMED NAME: INTEGRATED HEALTH TECHNOLOGIES INC DATE OF NAME CHANGE: 20020912 FORMER COMPANY: FORMER CONFORMED NAME: CHEM INTERNATIONAL INC DATE OF NAME CHANGE: 19960716 8-K 1 inb8kjun24_2004.txt INTEGRATED BIOPHARMA, INC. FORM 8-K JUNE 24, 2004 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2004 Integrated BioPharma, Inc. -------------------------- (Exact name of registrant as specified in its charter) Delaware 000-28876 22-2407475 -------- --------- ---------- (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation or organization) Identification No.) 225 Long Avenue Hillside, New Jersey 07205 -------------------- ------ (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (973) 926-0816 Not Applicable (Former name or former address, if changed since last report) Item 5. Other Events and Regulation FD Disclosure. On June 24, 2004, Integrated BioPharma, Inc., a Delaware corporation (the "Company"), issued a press release announcing that the Company had approved a stock repurchase program authorizing the Company to repurchase shares of the Company's common stock worth up to $3 million, and that the Company was not aware of any reason for the recent unusual trading activity affecting its common stock. The press release is attached as an exhibit to this Report. Item 7. Financial Statements and Exhibits (c) Exhibits. Exhibit No. Description - ----------- ----------- 99.1 Press Release issued by Integrated BioPharma, Inc. on June 24, 2004 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: June 25, 2004 INTEGRATED BIOPHARMA, INC. By: /s/ Eric Friedman --------------------- Eric Friedman Vice President and Chief Financial Officer Exhibit Index Exhibit No. Description - ----------- ----------- 99.1 Press Release issued by Integrated BioPharma, Inc. on June 24, 2004 EX-99 2 exhibit99_1.txt INTEGRATED BIOPHARMA, INC. - JUNE 24, 2004 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Contact: Jamie E. Levey June 24, 2004 Investor Relations (888) 319-6962 Integrated BioPharma Responds to Recent Trading Activity Hillside, N.J., June 24, 2004--Integrated BioPharma, Inc. (AMEX:INB) commented that it knows of no reason for the recent unusual trading activity affecting its common stock. Integrated BioPharma's management is not aware of any material adverse change in the business or in the economic fundamentals of the company. Based upon the current price of its common stock, the Company has adopted a stock repurchase plan giving management autonomy to purchase up to $3 million worth of the company's stock in open market transactions or privately negotiated transactions at the company's discretion. INB serves the pharmaceutical, biotech and nutraceutical industries. Through several wholly owned subsidiaries, INB develops, manufactures and distributes more than 130 products worldwide. Its subsidiary, Paxis Pharmaceuticals, Inc., develops and operates a state-of-the-art GMP facility for the production and sale of paclitaxel and related drugs. Through its biotech subsidiary, NuCycle Therapy, Inc., INB is developing human therapeutics and preventive cancer compounds in plants. Further information is available at www.iBioPharma.com. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission. -----END PRIVACY-ENHANCED MESSAGE-----